On the chart you can see the default numbers in dynamics for United Therapeutics Corporation (UTHR). Companys revenue shows the average of 818.108 M which is 0.791 % gowth. The average gross profit for the whole period is 745.38 M which is -0.009 %. The average gross profit ratio is 0.726 %. The net income growth for the company last year performance is 0.354 % which equals 0.496 % % on average for the whole company history.,
Diving into the fiscal trajectory of United Therapeutics Corporation, we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to 0. A look back at the past year reveals a total asset change of 0.186. In the realm of current assets, UTHR clocks in at 3551 in the reporting currency. A significant portion of these assets, precisely 2994.1, is held in cash and short-term investments. This segment shows a change of -0.279% when juxtaposed with last year's data. Long-term investments of the company, while not its focus, stand at 1909.8, if any, in the reporting currency. This indicates a difference of 45.100% from the last reporting period, reflecting the company's strategic shifts. The debt profile of the company shows a total long-term debt of 300 in the reporting currency. This figure signifies a year_over_year change of -0.125%. Shareholder value, as depicted by the total shareholder equity, is valued at 5984.8 in the reporting currency. The year over year change in this aspect is 0.248%. A deeper dive into the company's financials reveals additional details. The net receivables are valued at 278.9, with an inventory valuation of 111.8, and goodwill valued at 33.7, if any. The total intangible assets, if present, are valued at 80.5.
The financial landscape of United Therapeutics Corporation has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of 0.126. The company recently extended its share capital by issuing 6.6, marking a difference of 0.000 compared to the previous year. The company's investing activities resulted in net cash usage, amounting to -719600000.000 in the reporting currency. This is a shift of -0.113 from the previous year. In the same period, the company recorded 53.2, -23, and -100, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of 0.000, with a year over year difference of 0.000. Furthermore, the company allocated -98 for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as 193.3, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.
United Therapeutics Corporation's revenue saw a change of 0.202% compared with the previous period. The gross profit of UTHR is reported to be 2070. The company's operating expenses are 885.1, showing a change of 9.285% from the last year. The expenses for depreciation and amortization are 53.2, which is a 9.640% change from the last accounting period. Operating expenses are reported to be 885.1, which shows a 9.285% year-over-year change. Selling and marketing expenses are 0, which is a 0.000% change compared to the previous year. The EBITDA based on the recent numbers is 0, representing a 0.209% year-over-year growth. The operating income is 1184.9, which shows a 0.209% change when compared to the previous year. The change in the net income is 0.354%. The net income for the last year was 984.8.
